Navigation Links
Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment
Date:5/23/2013

THURSDAY, May 23 (HealthDay News) -- Although a study in 2012 suggested a cancer drug could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now say they have been unable to duplicate those findings.

The teams said their research could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has serious side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash.

"Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer drug with severe side effects," said study co-author Robert Vassar, a professor of cell and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago. "This practice should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering effects of bexarotene."

The U.S. Food and Drug Administration approved bexarotene in 1999 to treat refractory cutaneous T-cell lymphoma. Once approved, however, the drug also was available by prescription for "off-label" uses.

The 2012 study suggested that bexarotene was able to rapidly reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the initial study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the development of Alzheimer's.

Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the latest research, admitted being skeptical about the initial findings.

"We were surprised and excited -- even stunned -- when we first saw these results presented at a small conference," Sisodia said in a University of Chicago Medical Center news release. "The mechanism of action made some sense, but the assertion that they could reduce the areas of plaque by 50 percent within three days and by 75 percent in two weeks seemed too good to be true."

In attempting to duplicate the findings, the research teams found that they were indeed too good to be true.

"We all went back to our labs and tried to confirm these promising findings," Sisodia said. "We repeated the initial experiments -- a standard process in science. Combined results are really important in this field. None of us found anything like what they described in the 2012 paper."

Researchers at the University of Chicago, Northwestern University, Massachusetts General Hospital, Washington University in St Louis and the University of Tubingen in Germany reported in the May 24 issue of the journal Science that they did not find any reduction in beta amyloid plaques during or after treatment with bexarotene in three different strains of mice.

Bexarotene has never been tested on people as a treatment for Alzheimer's disease. Currently, there is no cure or effective treatment for the progressive condition, which affects an estimated 5.3 million Americans.

More information

The U.S. National Institutes of Health provides more information on Alzheimer's disease.

-- Mary Elizabeth Dallas

SOURCE: University of Chicago Medical Center, news release, May 23, 2013.


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Scientists solving the mystery of human consciousness
2. Scientists uncover multiple faces of deadly breast cancer
3. Scientists identify major source of cells defense against oxidative stress
4. Scientists tailor cell surface targeting system to hit organelle ZIP codes
5. Scientists rewrite rulebook on breast cancer in landmark global study
6. Warwick scientists uncover how checkpoint proteins bind chromosomes
7. NIH scientists link quickly spreading gene to Asian MRSA epidemic
8. Joslin scientists identify important mechanism that affects the aging process
9. Scripps Research scientists show how memory B cells stay in class to fight different infections
10. Scientists Map Melanomas Genome
11. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment
(Date:1/20/2017)... ... , ... Source Vitál Apothecary, a skin and body care company dedicated to ... had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference ... the nutritional, sports and health industries a chance to meet in private sessions with ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice ... in families with school-aged children since the holiday season. , “It happens every ... their families, sharing hugs and taking photos, which is the head-to-head gateway that lice ...
(Date:1/20/2017)... boca raton florida (PRWEB) , ... January 20, 2017 , ... ... trial at the Dana Farber Cancer Institute. For Betsy, the clinical trial has ... and her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Mary Magdalene: ... the mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace ... denizen, who spent her career as an educator interacting with countless women who had ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how ... You” is the creation of published author, Stephen Miller, who, for over ten long years ... given to him. Born in Trinidad and Tobago, he has been serving the Lord for ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Avillion LLP, a co-developer and financier of late-stage pharmaceutical ... MBA as Chief Medical Officer. Dr Weinberg will be based in ... ... more than 17 years as a pharmaceutical and biotech executive with ... the course of his career, he has interfaced with the US ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
(Date:1/19/2017)... 19, 2017 This report on the opioid ... scenario of the global market. Large number of chronic ... chronic constipation is a major side effect of consumption ... novel targeted therapy has been prescribed to treat opioid ... targeted medicines, and growing awareness about the therapy are ...
Breaking Medicine Technology: